DAEWOONG PHARMA ((주)대웅제약)
KOSPI Stock Code: 069620 | DART Corp Code: 00427483
English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.
| English name (as registered with DART) | DAEWOONG PHARMA |
|---|---|
| Korean legal name | (주)대웅제약 |
| Alternate names | 대웅제약 |
| Market | KOSPI |
| Stock Code | 069620 |
| DART Corp Code | 00427483 |
| CEO | 이창재, 박성수 |
| Business Registration No. | 1248601143 |
| Corporate Registration No. | 1348110075342 |
| Established Date | 2002-10-01 |
| Fiscal Month | 12 |
| KSIC Industry Code | 212 |
| Address (KO) | 경기도 화성시 향남읍 제약공단4길 35-14 - |
| Homepage | https://www.daewoong.co.kr/ |
| source_url | https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001528 |
| verified_at | 2026-11-01T02:24:25.826Z |
Annual Financial Summary (KRW)
Fiscal Year: 2025 | Basis: CFS (Consolidated) | Currency: KRW | Filing Source: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001528
| Account | FY2025 (Current) | FY2024 (Prior) |
|---|---|---|
| Revenue (매출액) | KRW 1,570,891,005,329 | KRW 1,422,683,296,380 |
| Operating Income (영업이익) | KRW 196,782,415,375 | KRW 147,942,198,476 |
| Net Income (당기순이익) | KRW 192,908,919,078 | KRW 23,346,508,507 |
| Total Assets (자산총계) | KRW 2,362,799,296,077 | KRW 1,976,977,110,511 |
| Total Liabilities (부채총계) | KRW 1,228,143,539,378 | KRW 1,049,992,505,369 |
| Total Equity (자본총계) | KRW 1,134,655,756,699 | KRW 926,984,605,142 |
Recent DART Filings (Last 90 Days, up to 20)
| Filed Date | Receipt No. | English Title | Korean Title | Filer |
|---|---|---|---|---|
2026-09-09 | 20260909000373 | Report on the Appointment, Dismissal or Early Retirement of Independent Directors | 독립이사의선임ㆍ해임또는중도퇴임에관한신고 | 대웅제약 |
2026-09-09 | 20260909800396 | Outcome of Extraordinary Shareholders' Meeting | 임시주주총회결과 | 대웅제약 |
2026-09-04 | 20260904800640 | Decision on Provision of Debt Guarantee for Others | 타인에대한채무보증결정 | 대웅제약 |
2026-09-02 | 20260902800508 | Filing or Application of Lawsuit, etc. (Claim of over Certain Amount) | 소송등의제기ㆍ신청(일정금액이상의청구) | 대웅제약 |
2026-08-25 | 20260825000279 | Reference documents for proxy solicitation | 의결권대리행사권유참고서류 | 대웅제약 |
2026-08-25 | 20260825000278 | Announcement of convocation of general meeting of shareholders | 주주총회소집공고 | 대웅제약 |
2026-08-21 | 20260821000287 | Report on status of specific securities, etc. owned by executives and major shareholders | 임원ㆍ주요주주특정증권등소유상황보고서 | 국민연금공단 |
2026-08-14 | 20260814002515 | Semi-annual Report (2026.06) | 반기보고서 (2026.06) | 대웅제약 |
Source & Disclaimer
source_url: https://dart.fss.or.kr/dsaf001/main.do?rcpNo=20260318001528 | verified_at: 2026-11-01T02:24:25.826Z
Data from Korea's Financial Supervisory Service (DART) and National Tax Service. FSS does not guarantee accuracy or completeness. Figures in KRW as filed. Not investment advice. English names are as registered with DART and may differ from the Korean legal name. Use corp_code, stock_code, or business registration number to identify a company.